[Form 4] Imunon, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Imunon, Inc. (IMNN) reporting person Stacy Lindborg, President & CEO and director, had 1,667 restricted shares vest on September 6, 2025, resulting in an acquisition of 1,667 common shares at $0 per share. After the vesting, Ms. Lindborg beneficially owned 3,584 shares directly and 234 shares indirectly through a 401(k) plan. The filing notes corporate equity adjustments: a 1-for-15 reverse stock split effective July 25, 2025, and a 15% stock dividend paid August 21, 2025, which adjusted previously reported share amounts. The Form 4 was signed by an attorney-in-fact on September 9, 2025.

Positive

• Executive alignment: Vesting of 1,667 restricted shares converts to common stock, aligning the CEO's interests with shareholders
• Transparent disclosure: Filing notes both the 1-for-15 reverse split and the 15% stock dividend, clarifying adjusted share amounts

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine executive equity vesting converted restricted stock into common shares; ownership changes reflect corporate equity actions.

The report documents the scheduled vesting of 1,667 restricted shares awarded on September 6, 2024, which vested in full on the first anniversary and converted one-for-one into common stock on September 6, 2025. Post-transaction direct beneficial ownership is 3,584 shares, with an additional 234 shares held indirectly via a 401(k). The filing also discloses a 1-for-15 reverse split and a 15% stock dividend that adjusted historic and outstanding award quantities. This is a standard insider vesting event with no cash consideration and no indication of open-market purchases or sales in this filing.

Corporate Governance Expert

TL;DR: Vesting aligns executive compensation with time-based retention; disclosures of corporate actions are properly noted.

The Form 4 shows time-based restricted stock fully vested per grant terms, demonstrating enforcement of the one-year cliff vesting schedule. The filing includes clear disclosure of the reverse split and stock dividend adjustments, which is important for accurate reporting of ownership and award sizes. There is no evidence in this filing of unusual timing or related-party transactions; the transaction appears consistent with typical equity compensation practices for senior officers who also serve as directors.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lindborg Stacy

(Last) (First) (Middle)

C/O IMUNON, INC.

997 LENOX DRIVE, SUITE 100

(Street)

LAWRENCEVILLE NJ 08648

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
09/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/06/2025		M		1,667(1)	A	$0	3,584	D
Common Stock								234	I	By 401(k) Plan

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock	(2)	09/06/2025		M			1,667	(3)	(3)	Common Stock	1,667	$0	0	D

Explanation of Responses:

1. Acquisition of common stock resulting from vesting of 100% of the restricted stock granted to Ms. Lindborg on September 6, 2024.

2. Each restricted stock share represents a contingent right to receive one share of Imunon, Inc.'s common stock.

3. On September 6, 2024, Ms. Lindborg received restricted stock representing 1,667 shares (as adjusted for the reverse stock split) subject to a one-year vesting schedule, vesting 100% on the first anniversary of the grant date. As restricted stock shares vest, the vested shares are automatically converted to vested common stock on a one-for-one basis on the vesting date.

Remarks:

On July 25, 2025, the Issuer effected a reverse stock split of Issuer Common Stock at a ratio of 1-for-15 (the "Reverse Stock Split"). As a result of the Reverse Stock Split, the shares of Issuer Common Stock, and the exercise price and shares of Issuer Common Stock underlying outstanding equity awards, have been adjusted accordingly versus any amounts previously reported by the Reporting Person. On August 21, 2025, the Issuer paid a 15% stock dividend, 0.15 shares of common stock per share of the Issuer's issued and outstanding shares of common stock, to stockholders of record as of August 7, 2025. As a result of the stock dividend, the shares of Issuer Common Stock have been adjusted accordingly versus any amounts previously reported by the Reporting Person.

	/s/ Susan Eylward, Attorney-in-Fact for Stacy Lindborg	09/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Stacy Lindborg report on Form 4 for IMNN?

Ms. Lindborg reported the vesting and automatic conversion of 1,667 restricted shares into common stock on September 6, 2025.

How many IMNN shares does Stacy Lindborg beneficially own after the transaction?

After the reported vesting, Ms. Lindborg beneficially owns 3,584 shares directly and 234 shares indirectly via a 401(k) plan.

Was any cash paid for the vested shares in the Form 4 filing?

No cash was paid; the shares were acquired upon vesting at a price of $0 per share.

Did Imunon disclose any corporate actions affecting share counts?

Yes. The issuer effected a 1-for-15 reverse stock split on July 25, 2025, and paid a 15% stock dividend on August 21, 2025, which adjusted reported share amounts.

Who signed the Form 4 for Stacy Lindborg and when?

The Form 4 was signed by Susan Eylward, Attorney-in-Fact for Stacy Lindborg on September 9, 2025.